Jinglan Zhou
Vertex Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jinglan Zhou.
Proceedings of the National Academy of Sciences of the United States of America | 2009
Fredrick Van Goor; Sabine Hadida; Peter D. J. Grootenhuis; B. Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani K. Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason Mccartney; Vijayalaksmi Arumugam; Caroline J. Decker; Jennifer Yang; Christopher Young; Eric R. Olson; Jeffery J. Wine; Raymond A. Frizzell; Melissa A. Ashlock; Paul Negulescu
Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung. Most CF mutations either reduce the number of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both. There are currently no approved therapies that target CFTR. Here we describe the in vitro pharmacology of VX-770, an orally bioavailable CFTR potentiator in clinical development for the treatment of CF. In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl− secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈10-fold, to ≈50% of that observed in HBE isolated from individuals without CF. Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures. These results support the hypothesis that pharmacological agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.
Journal of Organic Chemistry | 2015
Jinglan Zhou; Erica L. Campbell-Conroy; Alina Silina; Johnny Uy; Fabrice Jean Denis Pierre; Dennis James Hurley; Nicole Hilgraf; Bryan A. Frieman; Michael Paul Deninno
An array of six pyridyl-substituted fused bicyclic piperidines was prepared as novel cores for medicinal chemistry. For maximum diversity, the size of the fused ring varied from three to six atoms and contained up to two oxygen atoms. The pyridine ring was incorporated to improve physicochemical properties and to challenge the robustness of the chemistry. The presence of the pyridine did interfere with our initial approaches to these molecules, and in several instances, a blocking strategy had to be employed. These new scaffolds possess high sp3 character and may prove useful in multiple medicinal chemistry applications.
Tetrahedron Letters | 1999
Jinglan Zhou; Andreas Termin; Melissa Wayland; Christine M. Tarby
Abstract A series of 1,3-diamino-2-propanol derivatives have been synthesized on solid phase as potential aspartic acid protease inhibitors. The developed methodology allows the incorporation of either an alkyl group or H at the R 2 site of hydroxyethylamine isostere.
Archive | 2005
Urvi Sheth; Lev T. D. Fanning; Mehdi Numa; Hayley Binch; Dennis James Hurley; Jinglan Zhou; Sara S. Hadida Ruah; Anna Hazlewood; Alina Silina; Rajendran Vairagoundar; Fredrick Van Goor; Peter D. J. Grootenhuis; Martyn Botfield
Archive | 2013
Sarah Hadida-Ruah; Frederick Van Goor; Mark Miller; Jason Mccartney; Jinglan Zhou; Vijayalaksmi Arumugam
Archive | 2009
Sara Sabina Hadida-Ruah; Mark Miller; Jinglan Zhou; Brian Bear; Peter D. J. Grootenhuis
Archive | 2006
Ruah Sarah S. Hadida; Matthew Hamilton; Mark Miller; Peter D. J. Grootenhuis; Brian Bear; Jason Mccarthy; Jinglan Zhou
Archive | 2009
Sara S. Hadida Ruah; Mark Miller; Jinglan Zhou; Brian Bear
Archive | 2007
Sara S. Hadida Ruah; Peter D. J. Grootenhuis; Fredrick Van Goor; Jinglan Zhou; Brian Bear; Mark Miller; Jason Mccartney; Mehdi Numa
Archive | 2008
Sara S. Hadida Ruah; Mark Miller; Brian Bear; Jinglan Zhou; Jason Mccartney; Peter D. J. Grootenhuis